A tropism-transformed Oncolytic Adenovirus with Dual Capsid Modifications for enhanced Glioblastoma Therapy

Wang, Lizheng; Liu, Wenmo; Li, Zhe; Wang, Xupu; Feng, Xinyao; Wang, Zixuan; Wu, Jiaxin; Zhang, Haihong; Wu, Hui; Kong, Wei; Yu, Bin; Yu, Xianghui

doi:10.7150/jca.46463



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2020; 11(19):5713-5726. doi:10.7150/jca.46463 This issue Cite

Research Paper

A tropism-transformed Oncolytic Adenovirus with Dual Capsid Modifications for enhanced Glioblastoma Therapy

Lizheng Wang¹, Wenmo Liu¹, Zhe Li¹, Xupu Wang¹, Xinyao Feng¹, Zixuan Wang¹, Jiaxin Wu¹, Haihong Zhang¹, Hui Wu¹, Wei Kong^1,2, Bin Yu^1✉, Xianghui Yu^1,2✉

1. National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China.
2. Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China.

Citation:

Wang L, Liu W, Li Z, Wang X, Feng X, Wang Z, Wu J, Zhang H, Wu H, Kong W, Yu B, Yu X. A tropism-transformed Oncolytic Adenovirus with Dual Capsid Modifications for enhanced Glioblastoma Therapy. J Cancer 2020; 11(19):5713-5726. doi:10.7150/jca.46463. https://www.jcancer.org/v11p5713.htm

Other styles

Abstract

Glioblastoma, the most common human brain tumor, is highly invasive and difficult to cure using conventional cancer therapies. As an alternative, adenovirus-mediated virotherapies represent a popular and maturing technology. However, the cell surface coxsackievirus and adenovirus receptor (CAR)-dependent infection mechanism limits the infectivity and oncolytic effects of Adenovirus type 5. To address this limitation, in this study we aimed to develop a novel oncolytic adenovirus for enhanced infectivity and therapeutic efficacy toward glioblastoma. We developed a novel genetically modified oncolytic adenovirus vector with dual capsid modifications to facilitate infection and specific cytotoxicity toward glioma cells. Modification of the adenoviral capsid proteins involved the incorporation of a synthetic leucine zipper-like dimerization domain into the capsid protein IX (pIX) of human adenovirus serotype 5 (Ad5) and the exchange of the fiber knob from Ad37. The virus infection mechanism and anti-tumor efficacy of modified vectors were evaluated in both in vitro (cell) and in vivo (mouse) models. Ad37-knob exchange efficiently promoted the virus infection and replication-induced glioma cell lysis by oncolytic Ad5. We also found that gene therapy mediated by the dual-modified oncolytic Ad5 vector coupled with the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) exhibited significantly enhanced anti-tumor efficacy in vitro and in vivo. This genetically modified oncolytic adenovirus provides a promising vector for future use in glioblastoma gene-viral-based therapies.

Keywords: Glioblastoma, oncolytic adenovirus, TRAIL, Ad37, fiber knob

Citation styles

APA

Wang, L., Liu, W., Li, Z., Wang, X., Feng, X., Wang, Z., Wu, J., Zhang, H., Wu, H., Kong, W., Yu, B., Yu, X. (2020). A tropism-transformed Oncolytic Adenovirus with Dual Capsid Modifications for enhanced Glioblastoma Therapy. Journal of Cancer, 11(19), 5713-5726. https://doi.org/10.7150/jca.46463.

ACS

Wang, L.; Liu, W.; Li, Z.; Wang, X.; Feng, X.; Wang, Z.; Wu, J.; Zhang, H.; Wu, H.; Kong, W.; Yu, B.; Yu, X. A tropism-transformed Oncolytic Adenovirus with Dual Capsid Modifications for enhanced Glioblastoma Therapy. J. Cancer 2020, 11 (19), 5713-5726. DOI: 10.7150/jca.46463.

NLM

CSE

Wang L, Liu W, Li Z, Wang X, Feng X, Wang Z, Wu J, Zhang H, Wu H, Kong W, Yu B, Yu X. 2020. A tropism-transformed Oncolytic Adenovirus with Dual Capsid Modifications for enhanced Glioblastoma Therapy. J Cancer. 11(19):5713-5726.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.